Prevalence Of Hyperhomocysteinemia In Thai Chronic Kidney Disease (CKD) Patients

It is well recognized that patients with chronic kidney disease (CKD) have an increased risk for cardiovascular disease (CVD) and hyperhomocysteinemia appears to be a predictor of future CVD events. Hyperhomocysteinemia has been reported to bo of high prevalence in patients with CKD. The investigators aim to study the prevalence of hyperhomocysteinemia in Thai CKD patients by using Thai Screening and Early Evaluation of Kidney Disease (SEEK) study database and their relationship to CVD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Disease Amino Acid Metabolism, Inborn Errors Avitaminosis Cardiovascular Diseases Chronic Disease Congenital, Hereditary, and Neonatal Diseases and Abnormalities Deficiency Diseases Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genetic Diseases, Inborn Hyperhomocysteinemia Kidney Diseases Malabsorption Syndromes Male Urogenital Diseases Malnutrition Metabolic Diseases Metabolism, Inborn Errors Nutrition Disorders Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases Vitamin B Deficiency

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

About this study

Ninety eight subjects were sampling from Thai SEEK study database Traditional Traditional risk factors of CVD such as total cholesterol, triglyceride, age, sex, history of smoking and blood pressure levels were examined and recorded. Stored sera of these subjects were analyzed for the total homocysteine (tHcy) level. Analysis of variance was used to evaluate the different of mean tHcy among groups

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CKD stages 3-4 from Thai SEEK Study

Exclusion criteria

CKD stage 5

Treatment and study plan

Primary outcomes

Level of Homocysteine

Time frame: 3 months

Level of homocysteinemia according to each CKD level

Secondary outcomes

Association of cardiovascular event to the level of homocysteine

Time frame: 3 months

Hugh level of homocysteine will have association with cardiovascular events or not

Sponsors and collaborators

Lead sponsor

Bangkok Metropolitan Administration Medical College and Vajira Hospital

Other Gov

Registry information

Official study title

Prevalence Of Hyperhomocysteinemia In Thai CKD Patients And Relationship To Cardiovascular Events: Subgroup Analysis From Thai SEEK Study

Important dates

Study start: 2010
Primary completion: 2010
Study completion: 2011
First posted: Jul 12, 2011
Registry last updated: Jul 12, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed